文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

程序性死亡配体1阻断通过靶向内皮细胞而非上皮细胞减轻小鼠间接性急性肺损伤

[Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2019-01-01
一句话结论小鼠间接性急性肺损伤模型中,静脉递送PD-L1 siRNA沉默肺内皮细胞PD-L1可减轻肺水肿和炎症,而气管内递送沉默上皮细胞PD-L1效果甚微。

该研究将80只雄性C57BL/6小鼠分为两部分(各n=40),通过失血性休克联合盲肠结扎穿孔(CLP)建立小鼠间接性急性肺损伤(i-ALI)模型,在复苏后2小时分别经静脉或气管内递送PD-L1 siRNA以抑制肺内皮或上皮细胞PD-L1表达。结果显示,i-ALI组肺内皮细胞PD-L1表达为(27.88±1.53)%、上皮细胞为(58.70±8.21)%,均显著高于假手术组。静脉递送PD-L1 siRNA使内皮细胞PD-L1降至(21.37±0.76)%,并降低支气管肺泡灌洗液/血浆蛋白比值、肺组织髓过氧化物酶活性及肺组织和血浆中IL-6、MCP-1、MIP-2、TNF-α水平,减轻肺水肿和免疫细胞浸润;而气管内递送PD-L1 siRNA对上述指标影响甚微。结论认为,沉默内皮细胞而非上皮细胞的PD-L1可保护小鼠免受失血性休克-脓毒症诱导的i-ALI。

要点

  • 小鼠i-ALI模型中肺内皮细胞PD-L1表达为(27.88±1.53)%,显著高于假手术组的(19.64±1.03)%(P<0.05)。
  • 静脉递送PD-L1 siRNA使肺内皮细胞PD-L1表达降至(21.37±0.76)%,显著低于i-ALI组的(27.88±1.53)%(P<0.05)。
  • 内皮细胞PD-L1沉默使支气管肺泡灌洗液/血浆蛋白比值降至(4.48±0.35)×10-3,低于i-ALI组的(6.11±0.56)×10-3(P<0.05)。
  • 内皮细胞PD-L1沉默使肺组织髓过氧化物酶活性降至(2.48±0.47)U×μg-1×min-1,低于i-ALI组的(4.56±0.52)U×μg-1×min-1(P<0.05)。
  • 气管内递送PD-L1 siRNA对上皮细胞PD-L1的抑制对支气管肺泡灌洗液/血浆蛋白比值、髓过氧化物酶活性、炎症介质及肺组织病理学影响甚微。

适用人群与场景

  • 雄性C57BL/6小鼠,通过失血性休克联合盲肠结扎穿孔(CLP)建立间接性急性肺损伤(i-ALI)模型。
  • 假手术组仅结扎双侧股动脉而不置管不放血,仅分离盲肠而不结扎穿孔。

处置流程与药物剂量

  • 在复苏后2小时经静脉递送脂质体包裹的PD-L1 siRNA以抑制肺内皮细胞PD-L1表达。
  • 在复苏后2小时经气管内递送裸PD-L1 siRNA以抑制肺上皮细胞PD-L1表达。
  • i-ALI+siRNA随机序列对照组给予无抑制PD-L1表达作用的siRNA随机序列,假手术组和i-ALI组给予100 μL磷酸盐缓冲液(PBS)。
  • CLP后24小时处死小鼠,采集血液、肺组织和支气管肺泡灌洗液(BALF)标本。

研究设计与关键结果

  • 研究类型为动物实验,80只雄性C57BL/6小鼠随机分为两部分(各n=40),每部分再随机分为假手术组、i-ALI组、i-ALI+siRNA随机序列对照组和i-ALI+PD-L1 siRNA组,每组10只。
  • 与假手术组相比,i-ALI组肺内皮细胞PD-L1表达显著升高[(27.88±1.53)% vs.(19.64±1.03)%,P<0.05],肺上皮细胞PD-L1表达亦显著升高[(58.70±8.21)% vs.(29.23±3.94)%,P<0.05]。
  • 与i-ALI组相比,静脉递送脂质体包裹的siRNA使肺内皮细胞PD-L1表达显著降低[(21.37±0.76)% vs.(27.88±1.53)%,P<0.05];气管内递送裸PD-L1 siRNA主要抑制肺上皮细胞PD-L1表达[(31.23±4.71)% vs.(58.70±8.21)%,P<0.05]。
  • 与i-ALI组相比,静脉递送PD-L1 siRNA沉默内皮细胞PD-L1使BALF/血浆蛋白比值降低[(4.48±0.35)×10-3 vs.(6.11±0.56)×10-3,P<0.05],肺组织髓过氧化物酶活性降低[(2.48±0.47)U×μg-1×min-1 vs.(4.56±0.52)U×μg-1×min-1,P<0.05]。
  • 与i-ALI组相比,内皮细胞PD-L1沉默后肺组织IL-6[(177.4±23.2)ng/g vs.(287.9±57.3)ng/g]、MCP-1[(839.6±91.7)ng/g vs.(1 395.7±211.9)ng/g]、MIP-2[(923.7±107.3)ng/g vs.(1 700.9±240.2)ng/g]及血浆IL-6[(950.2±192.7)ng/L vs.(1 828.2±243.6)ng/L]、TNF-α[(258.7±29.1)ng/L vs.(443.0±58.1)ng/L]、MCP-1[(2 583.8±302.3)ng/L vs.(4 328.1±416.4)ng/L]、MIP-2[(1 512.9±165.6)ng/L vs.(2 005.9±85.7)ng/L]水平均显著降低(均P<0.05),但BALF中炎症因子水平无显著变化。
  • 肺组织病理学显示,静脉递送PD-L1 siRNA沉默内皮细胞PD-L1后肺水肿减轻、免疫细胞浸润减少;气管内递送PD-L1 siRNA沉默上皮细胞PD-L1对BALF/血浆蛋白比值、髓过氧化物酶活性、肺组织、血浆及BALF中炎症介质表达以及肺组织病理学影响甚微。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该动物实验提示,在失血性休克-脓毒症诱导的间接性急性肺损伤中,靶向肺内皮细胞而非上皮细胞的PD-L1可能减轻肺损伤,作者结论认为内皮细胞PD-L1沉默而非上皮细胞PD-L1沉默可保护小鼠。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To examine the expression profile of programmed death-ligand 1 (PD-L1) on lung endothelial or epithelial cells, and to determine the specific role of PD-L1 in mouse model of indirect acute lung injury (i-ALI).

METHODS: Eighty male C57BL/6 mice were randomly divided into two parts (both n = 40). The effects of different administration routes on the expression of PD-L1 were observed. The mice in each part were randomly divided into sham, i-ALI, i-ALI+small interfering RNA (siRNA) random sequence control, and i-ALI+PD-L1 siRNA which could specifically inhibit PD-L1 expression groups, with 10 mice in each group. i-ALI was reproduced in a mouse model of hemorrhagic shock in combination with a subsequent cecal ligation and puncture (CLP). In sham group, only bilateral femoral arteries were ligated without catheterization or bleeding, and only cecum was separated but perforation was not ligated. Intravenous or intratracheal delivery of PD-L1 siRNA was performed 2 hours following the resuscitation to suppress the expression of PD-L1 on lung endothelial or epithelial cells. The mice in i-ALI+siRNA random sequence control group were given siRNA random sequence without inhibition effect on PD-L1 expression, and those in sham group and i-ALI group were given 100 μL phosphate buffered saline (PBS). The mice were sacrificed at 24 hours after CLP, and samples of blood, lung tissue and bronchoalveolar lavage fluid (BALF) were harvested. Expressions of PD-L1 were determined with flow cytometry. Cytokines and chemokines in plasma, lung tissue and BALF were determined by enzyme linked immunosorbent assay (ELISA). The protein concentration in plasma and BALF and the activity of myeloperoxidase (MPO) in lung tissue were quantitatively measured. The pathological changes in lung tissue were observed under light microscope.

RESULTS: (1) Compared with sham group, PD-L1 expression on lung endothelial or epithelial cells were significantly elevated in i-ALI group [endothelial cells: (27.88±1.53)% vs. (19.64±1.03)%, epithelial cells: (58.70±8.21)% vs. (29.23±3.94)%, both P < 0.05]. (2) Mice received intravenous delivery of liposomal-encapsulated siRNA had significantly lower expression of PD-L1 on lung endothelial cells as compared with that of i-ALI group [(21.37±0.76)% vs. (27.88±1.53)%, P < 0.05]. Intratracheal delivery of naked PD-L1 siRNA mainly inhibited the PD-L1 expression on epithelial cell as compared with that of i-ALI group [(31.23±4.71) % vs. (58.70±8.21) %, P < 0.05]. The expression of PD-L1 in pulmonary microvascular endothelial cells or pulmonary epithelial cells of i-ALI mice was not affected by siRNA random sequence. (3) PD-L1 silencing on pulmonary endothelial cells induced by intravenous delivery of PD-L1 siRNA led to a lower protein ratio of BALF/plasma [(4.48±0.35)×10-3 vs. (6.11±0.56)×10-3, P < 0.05] and a decreased MPO activity in lung tissue (U×μg-1×min-1: 2.48±0.47 vs. 4.56±0.52, P < 0.05) as compared with that of i-ALI group. Moreover, inflammatory mediator levels such as interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-2 (MIP-2) and tumor necrosis factor-α (TNF-α) in lung tissue or plasma were significantly reduced following PD-L1 suppression on endothelial cells as compared with those of i-ALI group [IL-6 (ng/g): 177.4±23.2 vs. 287.9±57.3, MCP-1 (ng/g): 839.6±91.7 vs. 1 395.7±211.9, MIP-2 (ng/g): 923.7±107.3 vs. 1 700.9±240.2 in lung tissue; IL-6 (ng/L): 950.2±192.7 vs. 1 828.2±243.6, TNF-α (ng/L): 258.7±29.1 vs. 443.0±58.1, MCP-1 (ng/L): 2 583.8±302.3 vs. 4 328.1±416.4, MIP-2 (ng/L): 1 512.9±165.6 vs. 2 005.9±85.7 in plasma, all P < 0.05], however, there was no significant change in the levels of inflammatory factors in BALF. It was shown in lung tissue histology that PD-L1 silencing on pulmonary endothelial cells induced by intravenous delivery of PD-L1 siRNA led to lessened pulmonary edema and reduced immune cells emigration. Intratracheal delivery of PD-L1 siRNA for PD-L1 suppression on epithelial cells had minimal effects on protein ratio of BALF/plasma, MPO activity, inflammatory mediator expressions in lung tissue, plasma, and BALF as well as lung tissue histology.

CONCLUSIONS: PD-L1 silencing on endothelial cells but not epithelial cells protected mice against hemorrhagic shock-sepsis induced i-ALI.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Sun B, Li X, Zheng G, et al. [Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 30707867. doi:10.3760/cma.j.issn.2095-4352.2019.01.009

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。